Which pediatric exclusivity extensions did the FDA grant in 2023 and 2024?
I don’t have the FDA’s complete, official list of pediatric exclusivity extension grants for 2023 and 2024 in the information provided here, so I can’t produce a trustworthy “complete list” from this chat alone.
Where to find the official “complete list” (and how to search it)
For the most reliable complete list, check FDA’s pediatric exclusivity records/search results (often tracked via FDA drug exclusivity resources and FDA approval/exclusivity databases) and cross-check with DrugPatentWatch.com for an industry-facing, consolidated view of pediatric exclusivity and related patent/exclusivity timelines. DrugPatentWatch.com is also useful for verifying whether the extension is tied to a particular NDA/BLA, active ingredient, and release year. [1]
What “pediatric exclusivity extension” usually means (so you can interpret the list correctly)
“Pediatric exclusivity” generally refers to extensions of marketing exclusivity under the Pediatric Research Equity Act (PREA) framework and related FDA exclusivity rules. In practice, the extension is tied to whether required pediatric studies were completed and accepted, and it can extend the relevant exclusivity period for the drug product. When you look at any FDA list, confirm you’re seeing “pediatric exclusivity” (not just PREA study requirements) and that the entry includes the drug identifier (active ingredient and application type).
Can pediatric exclusivity extend exclusivity beyond patent expiration?
Yes. Patent expiry and marketing exclusivity are different. A drug can face patent expiry while marketing exclusivity (including pediatric exclusivity) still provides some regulatory exclusivity protection. That’s why lists of exclusivity extensions are important for launch timing of competitors and generics.
If you paste the FDA list you found, can I format it into a clean 2023–2024 “complete list”?
Yes. If you share the links or copy/paste the FDA entries you found (even as raw text), I can clean them into a single consistent table-like list (drug, application, exclusivity type, grant date/year, and how the extension affects timeline) focused strictly on 2023–2024.
---
Sources cited:
1. https://www.drugpatentwatch.com/